Cigna Group Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenues: $68.5 billion, reflecting strong performance.

Adjusted Earnings Per Share (EPS): $7.79, up 16% year-over-year.

After-tax Special Items Charges: $322 million or $1.22 per share.

Medical Care Ratio (MCR): 79.8% for Cigna Healthcare, favorable compared to expectations.

Earnings Growth: Cigna Healthcare's earnings grew 18% year-over-year.

2Strategic Updates and Business Highlights

Leadership Transition: David Cordani will transition to Executive Chair on July 1, with Brian Evanko stepping in as CEO.

Portfolio Shaping: Cigna announced plans to exit the individual exchange business by the end of 2026 and is reviewing strategic alternatives for eviCore.

Innovation in Pharmacy Benefits: The new rebate-free pharmacy benefits model, named [Signature], aims to improve affordability and transparency for consumers.

Evernorth Performance: Adjusted earnings from Evernorth Health Services grew 20% in Q1, driven by strong demand in specialty pharmacy and care services.

AI and Data Utilization: Cigna is leveraging AI to enhance customer experiences and drive affordability in care.

3Forward Guidance and Outlook

Adjusted EPS Guidance: Raised to at least $30.35 for the full year 2026.

Second Quarter Expectations: Anticipated adjusted EPS to be approximately 25% of the full year outlook.

Evernorth's Full Year Expectations: Adjusted income from operations projected at least $6.9 billion.

4Bad News, Challenges, or Points of Concern

Pharmacy Benefit Services (PBS) Earnings Decline: Earnings decreased by 28% year-over-year, attributed to large client renewals and investments in the new rebate-free model.

Individual Exchange Business Exit: The decision to exit this segment reflects challenges in achieving scale and focus, although it may free up some capital.

MCR Seasonality: The second quarter is expected to see a higher MCR due to typical seasonality and the impact of the individual exchange business.

5Notable Q&A Insights

Client Transition to New PBM Model: Clients are showing positive feedback on the new [Signature] model, with expectations of significant uptake by 2028.

Biosimilars Growth: The adoption of biosimilars is driving profitability, with specific programs like STELARA showing strong performance.

340B Exposure: Cigna's 340B activity is primarily service-based, focusing on partnerships with hospitals rather than being a scaled contract pharmacy.

GLP-1 Programs: Demand for GLP-1 drugs is stable, with employers balancing affordability against employee satisfaction. Overall, Cigna Group demonstrated strong financial performance in Q1 2026, with strategic initiatives aimed at enhancing customer experience and operational efficiency, despite facing challenges in specific segments. The leadership transition is positioned to further drive growth and innovation.